Bispecific DART antibody-based molecule to CD3ε and CD123, Flotetuzumab, has already shown interesting results, with a 30% CR in R/R CD123+ AML setting, while anti CD99 antibody has not yet been investigated [112]. Here, CD3E is linked to acute myeloid leukemia.